JP2010132694A5 - - Google Patents

Download PDF

Info

Publication number
JP2010132694A5
JP2010132694A5 JP2010041778A JP2010041778A JP2010132694A5 JP 2010132694 A5 JP2010132694 A5 JP 2010132694A5 JP 2010041778 A JP2010041778 A JP 2010041778A JP 2010041778 A JP2010041778 A JP 2010041778A JP 2010132694 A5 JP2010132694 A5 JP 2010132694A5
Authority
JP
Japan
Prior art keywords
formulation
oxcarbazepine
oxacarbazepine
sieve
maximum residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010041778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010132694A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010132694A publication Critical patent/JP2010132694A/ja
Publication of JP2010132694A5 publication Critical patent/JP2010132694A5/ja
Pending legal-status Critical Current

Links

JP2010041778A 1997-02-14 2010-02-26 オキサカルバゼピンフィルム被覆錠剤 Pending JP2010132694A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005346338A Division JP2006077029A (ja) 1997-02-14 2005-11-30 オキサカルバゼピンフィルム被覆錠剤

Publications (2)

Publication Number Publication Date
JP2010132694A JP2010132694A (ja) 2010-06-17
JP2010132694A5 true JP2010132694A5 (enExample) 2012-05-31

Family

ID=4184588

Family Applications (3)

Application Number Title Priority Date Filing Date
JP10535347A Withdrawn JP2000511935A (ja) 1997-02-14 1998-02-12 オキサカルバゼピンフィルム被覆錠剤
JP2005346338A Withdrawn JP2006077029A (ja) 1997-02-14 2005-11-30 オキサカルバゼピンフィルム被覆錠剤
JP2010041778A Pending JP2010132694A (ja) 1997-02-14 2010-02-26 オキサカルバゼピンフィルム被覆錠剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP10535347A Withdrawn JP2000511935A (ja) 1997-02-14 1998-02-12 オキサカルバゼピンフィルム被覆錠剤
JP2005346338A Withdrawn JP2006077029A (ja) 1997-02-14 2005-11-30 オキサカルバゼピンフィルム被覆錠剤

Country Status (31)

Country Link
US (2) US20070036863A1 (enExample)
EP (1) EP0966287B1 (enExample)
JP (3) JP2000511935A (enExample)
KR (3) KR19980071337A (enExample)
CN (2) CN1170542C (enExample)
AR (1) AR011142A1 (enExample)
AT (1) ATE239481T1 (enExample)
AU (1) AU738030B2 (enExample)
BR (1) BR9807368A (enExample)
CA (1) CA2277791C (enExample)
CO (1) CO4920215A1 (enExample)
CY (1) CY2480B1 (enExample)
CZ (1) CZ298840B6 (enExample)
DE (1) DE69814367T2 (enExample)
DK (1) DK0966287T3 (enExample)
ES (1) ES2199422T3 (enExample)
HU (1) HU227807B1 (enExample)
ID (1) ID22348A (enExample)
MY (1) MY117582A (enExample)
NO (1) NO327486B1 (enExample)
NZ (1) NZ336946A (enExample)
PE (1) PE58999A1 (enExample)
PL (1) PL193332B1 (enExample)
PT (1) PT966287E (enExample)
RU (1) RU2201218C2 (enExample)
SK (1) SK284503B6 (enExample)
TR (1) TR199901804T2 (enExample)
TW (1) TW529957B (enExample)
UY (1) UY24888A1 (enExample)
WO (1) WO1998035681A1 (enExample)
ZA (1) ZA981205B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
PL371259A1 (pl) 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
MXPA06002392A (es) 2003-09-03 2006-06-20 Novartis Ag Uso de oxcarbazepina para el tratamiento de dolor neuropatico diabetico y la mejora del sueno.
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
CN103893145A (zh) 2005-09-23 2014-07-02 弗·哈夫曼-拉罗切有限公司 新型制剂
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
CA2630240A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2010499A4 (en) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF OXCARBAZEPINE PARTICULATE FROM 15 TO 30 MICRONS IN AVERAGE
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
JP2010513324A (ja) 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
EP2146699A2 (en) * 2007-05-23 2010-01-27 Ratiopharm GmbH Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Similar Documents

Publication Publication Date Title
JP2010132694A5 (enExample)
PH12015501782A1 (en) Method for production of commercial nanoparticles and microparticle powders
CN104288154B (zh) 一种含有不同粒径范围的法匹拉韦药物组合物
SG10201805657PA (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
JP2015501783A5 (enExample)
IL192374A0 (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
NZ609840A (en) Process for making multiparticulate gastroretentive dosage forms
JP2012255026A5 (enExample)
JP2013047831A5 (enExample)
MX359793B (es) Producción de nanopartículas encapsuladas a escala comercial.
WO2009108865A3 (en) Tablets and preparation thereof
JP2016539953A5 (enExample)
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
WO2015003479A3 (zh) 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法
MX350531B (es) Granulados que comprenden acetato de eslicarbazepina.
SA520411573B1 (ar) تحضير صور جرعة صلبة تشتمل على أجسام مضادة بعمل طبقات من المحلول/ المعلق
PL401676A1 (pl) Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
ZA201109262B (en) Process for the preparation of a spray powder comprising one or more glycine-n,n-diacetic acid derivatives and use of the spray powder for producing compression agglomerates
JP2015510935A5 (enExample)
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
CN106692095A (zh) 一种布瓦西坦药物口服缓释制剂及其制备方法
JP2009091362A5 (enExample)
RU2015146324A (ru) Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей
WO2006097725A3 (en) Pharmaceutical compositions comprising microparticles for delivery into neurons
ZA200805793B (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol